CN Mobile Logo


Prostate Cancer

Biomarker Combo Could Predict Prostate Cancer Survival

A combination of biomarkers has shown promise as a surrogate for survival in clinical trials of metastatic castration-resistant prostate cancer. Image © Eugene Sim / Shutterstock.com.

Prostate Cancer

The use of bone-seeking radionuclides effectively controlled bone pain in men with prostate cancer metastatic to the bone, according to the results of a systematic review.

A new meta-analysis suggests that survival outcomes are similar with intermittent and continuous androgen deprivation therapy, and that intermittent therapy may improve some quality-of-life criteria.

Six months of radiation therapy combined with ADT for prostate cancer may not produce a survival benefit in men with moderate to severe comorbidities.

There is ample evidence suggesting that physical activity and exercise can be therapeutic tools for patients with prostate cancer. Patients diagnosed with localized disease should be advised to stay physically active; furthermore, patients who are undergoing radiation therapy and/or treatment with ADT appear to benefit from regular aerobic and resistance exercise to alleviate side effects.

Despite the clearly established overall health benefits of exercise, its role in reducing prostate cancer risk is unclear. Whereas some studies found often dramatic reductions in prostate cancer risk, others found no effect.

Men with low-risk prostate cancer monitored by active surveillance are not likely to have their disease spread to other organs or die of their prostate cancer.

Perineural invasion was a significant predictor of increased risk for bone metastases in men with prostate cancer who had suspicion for bone metastases after a whole-body bone scan.


Subscribe to Prostate Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.